Levat 4 mg (Capsule)

Unit Price: ৳ 650.00 (1 x 30: ৳ 19,500.00)

Strip Price: ৳ 19,500.00

Medicine Details

Category	Details
Generic	Lenvatinib mesylate
Company	Jenphar bangladesh ltd
Also available as	Levat 10 mg capsule

Indications

Differentiated Thyroid Cancer
Renal Cell Carcinoma
Hepatocellular Carcinoma
Endometrial Carcinoma

Pharmacology

Kinase Inhibitor
Inhibition of VEGF receptors
Inhibition of FGF receptors
Platelet-derived growth factor receptor inhibition
Metabolism via CYP3A and aldehyde oxidase

Absorption

Occurrence of peak plasma concentration

Distribution

In vitro binding to human plasma proteins

Metabolism

Main metabolic pathways

Elimination

Terminal elimination half-life

Dosage

Differentiated Thyroid Cancer (DTC): 24 mg orally once daily
Renal Cell Carcinoma (RCC): 18 mg in combination with 5 mg Everolimus orally once daily
Hepatocellular Carcinoma (HCC): 12 mg for patients greater than or equal to 60 kg or 8 mg for patients less than 60 kg orally once daily
Endometrial Carcinoma: 20 mg orally once daily in combination with Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks

Administration

Capsules can be swallowed whole or dissolved in liquid

Interaction

Avoid coadministration with drugs that prolong the QT interval

Contraindications

Hypersensitivity to Lenvatinib or any component of the formulation

Side Effects

Hypertension
Cardiac Dysfunction
Arterial Thromboembolic Events
Hepatotoxicity
Renal Failure
Proteinuria
Diarrhea
Fistula Formation
Gastrointestinal Perforation
QT Interval Prolongation
Hypocalcemia
Reversible Posterior Leukoencephalopathy Syndrome
Hemorrhagic Events
Impairment of Thyroid Stimulating Hormone Suppression
Wound Healing Complications

Pregnancy & Lactation

Potential embryo-fetal harm
Use of effective contraception
Discontinuation of breastfeeding

Precautions & Warnings

Hypertension: Control and monitoring
Cardiac Dysfunction: Monitoring for symptoms
Arterial Thromboembolic Events: Discontinuation following an event
Hepatotoxicity: Liver function monitoring
Renal Failure or Impairment: Monitoring and dosing adjustments
Proteinuria: Monitoring and dosing adjustments
Diarrhea: Prompt management and dosing adjustments
Fistula Formation and Gastrointestinal Perforation: Discontinuation in severe cases
QT Interval Prolongation: Electrolyte abnormality correction and monitoring
Hypocalcemia: Resolution following supplementation
Reversible Posterior Leukoencephalopathy Syndrome: Monitoring and dosing adjustments
Hemorrhagic Events: Risk consideration and dosing adjustments
Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction: Thyroid function monitoring and treatment
Wound Healing Complications: Discontinuation prior to surgery

Use in Special Populations

Dosage Modifications for Severe Renal Impairment:
- Differentiated thyroid cancer
- Renal cell carcinoma
- Endometrial carcinoma
Dosage Modifications for Severe Hepatic Impairment:
- Differentiated thyroid cancer
- Renal cell carcinoma
- Endometrial carcinoma
Pediatric Use: Safety and effectiveness not established